Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
Despite extensive translational research, no validated biomarkers predictive of bevacizumab treatment outcome have been identified.
We performed a meta-analysis of individual patient data from six randomized phase III trials in colorectal, pancreatic, lung, renal, breast, and gastric cancer to explore the potential relationships between 195 common genetic variants in the vascular endothelial growth factor (VEGF) pathway and bevacizumab treatment outcome.
The analysis included 1,402 patients (716 bevacizumab-treated and 686 placebo-treated). Twenty variants were associated (P < 0.05) with progression-free survival (PFS) in bevacizumab-treated patients. Of these, 4 variants in EPAS1 survived correction for multiple testing (q < 0.05). Genotype-by-treatment interaction tests revealed that, across these 20 variants, 3 variants in VEGF-C (rs12510099), EPAS1 (rs4953344), and IL8RA (rs2234671) were potentially predictive (P < 0.05), but not resistant to multiple testing (q > 0.05). A weak genotype-by-treatment interaction effect was also observed for rs699946 in VEGF-A, whereas Bayesian genewise analysis revealed that genetic variability in VHL was associated with PFS in the bevacizumab arm (q < 0.05). Variants in VEGF-A, EPAS1, and VHL were located in expression quantitative loci derived from lymphoblastoid cell lines, indicating that they affect the expression levels of their respective gene.
This large genetic analysis suggests that variants in VEGF-A, EPAS1, IL8RA, VHL, and VEGF-C have potential value in predicting bevacizumab treatment outcome across tumor types. Although these associations did not survive correction for multiple testing in a genotype-by-interaction analysis, they are among the strongest predictive effects reported to date for genetic variants and bevacizumab efficacy.
KeywordsAnti-angiogenesis Bevacizumab Treatment outcome Genetic variant Predictive and prognostic biomarker
We thank all patients who volunteered to participate in the genetic biomarker protocol of these studies and the research staff at the Vesalius Research Center, in particular Gilian Peuteman, Dominiek Smeets, and Thomas Van Brussel. The trials included in this analysis were sponsored and funded by F. Hoffmann-La Roche, Basel, Switzerland. Funding for statistical analyses and third-party medical writing support for this paper were also provided by F. Hoffmann-La Roche. Sanne de Haas and Paul Delmar are employees of F. Hoffmann-La Roche Ltd. Matthieu Moisse is supported by the Fund for Scientific Research Flanders (FWO). The work of Peter Carmeliet is funded by long-term structural funding Methusalem by the Flemish Government. Diether Lambrechts is supported by the Seventh Framework Programme of the European Community for Research (AngioPredict). The trials included in this analysis were sponsored and funded by F. Hoffmann-La Roche, Basel, Switzerland. Funding for statistical analyses and third-party medical writing support for this paper were also provided by F. Hoffmann-La Roche.
Conflict of interest
Sanne de Haas and Paul Delmar are employees of F. Hoffmann-La Roche, Basel, Switzerland. Aruna T. Bansal is a paid consultant of F. Hoffmann-La Roche. Eric Van Cutsem, Diether Lambrechts, and Peter Carmeliet have received research funding from F. Hoffmann-La Roche related to research into biomarkers for bevacizumab. David Miles has received honoraria from F. Hoffmann-La Roche for advisory boards and speaker engagements. Celine Pallaud is a former employee of F. Hoffmann-La Roche, Basel, Switzerland. Stefan Scherer is a former employee of Genentech. The remaining authors have declared no potential conflict of interest.
- 4.Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239–3247. doi: 10.1200/JCO.2008.21.6457 PubMedCrossRefGoogle Scholar
- 5.Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252–1260. doi: 10.1200/Jco.2010.28.0982 PubMedCrossRefGoogle Scholar
- 9.Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17):2039–2045. doi: 10.1200/Jco.2012.42.0505 PubMedCrossRefPubMedCentralGoogle Scholar
- 10.Henriksoon R, Bottomley A, Mason W, Saran F, Wick W, Nishikawa R (2013) Progression-free survival and health-related quality of life in AVAglio, a phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 31 (Suppl. abstr 2005). http://meetinglibrary.asco.org/content/114612-132
- 19.Zhang W, Dahlberg SE, Yang D et al (2009) Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599 [abstr 8032]. J Clin Oncol 27(15 Suppl.):414s. http://meetinglibrary.asco.org/content/33186-65
- 20.Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672–4678. doi: 10.1200/JCO.2008.16.1612 PubMedCrossRefPubMedCentralGoogle Scholar
- 22.Gerger A, El-Khoueiry A, Zhang W et al (2011) Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 17(17):5783–5792. doi: 10.1158/1078-0432.CCR-11-1115 PubMedCrossRefPubMedCentralGoogle Scholar
- 24.Hansen TF, Christensen RD, Andersen RF, Spindler KLG, Johnsson A, Jakobsen A (2012) The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer results from the Nordic ACT trial. Int J Colorectal Dis 27(6):715–720. doi: 10.1007/S00384-011-1382-6 PubMedCrossRefGoogle Scholar
- 25.Schneider BP, Gray RJ, Radovich M et al (2013) Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res 19(5):1281–1289. doi: 10.1158/1078-0432.Ccr-12-3029 PubMedCrossRefPubMedCentralGoogle Scholar
- 26.Loupakis F, Cremolini C, Dongyun Y et al (2013) Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. Plos One 8(7):e66774. doi: 10.1371/journal.pone.0066774
- 35.Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate—a practical and powerful approach to multiple testing. J R Stat Soc B 57(1):289–300Google Scholar
- 39.Friedman J, Hastie T, Tibshirani R (2008) Regularization paths for generalized linear models via coordinate descent. J Stat Soft 33:1–22Google Scholar
- 40.Simon N, Friedman J, Hastie T, Tibshirani R (2011) Regularization paths for Cox’s proportional hazards model via coordinate descent. J Stat Soft 39:1–13Google Scholar
- 44.Xia GB, Kageyama Y, Hayashi T, Kawakami S, Yoshida M, Kihara M (2001) Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (EPAS1) and possible involvement of EPAS1 in the angiogenesis of renal cell carcinoma. Cancer 91(8):1429–1436. doi: 10.1002/1097-0142(20010415)91:8<1429:Aid-Cncr1149>3.0.Co;2-V PubMedCrossRefGoogle Scholar
- 46.Favier J, Lapointe S, Maliba R, Sirois MG (2007) HIF2 alpha reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma. BMC Cancer 7. doi: 10.1186/1471-2407-7-139
- 49.Talks KL, Turley H, Gatter KC et al (2000) The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157(2):411–421. doi: 10.1016/S0002-9440(10)64554-3 PubMedCrossRefPubMedCentralGoogle Scholar